About GIANT BioSystems

Founded in 2023, GIANT BioSystems emerged from a critical need to address one of the most pressing challenges in modern healthcare: antimicrobial resistance (AMR).

As antibiotic-resistant infections continue to rise globally, healthcare providers face increasing difficulty in selecting effective treatments. Traditional antimicrobial susceptibility testing (AST) methods require 48–72 hours to deliver results, forcing clinicians to rely on empirical treatment that may be ineffective or unnecessarily broad-spectrum.

GIANT BioSystems was created to bridge this gap. Our innovative platform delivers comprehensive AST results in a fraction of the time, enabling precision medicine approaches that improve patient outcomes while combating the spread of resistance.

Rapid Antimicrobial Susceptibility Testing

Our core mission is to provide healthcare professionals with rapid, accurate, and comprehensive antimicrobial susceptibility testing. By reducing the time to results from days to hours, we empower clinicians to:

• ✓ Make informed treatment decisions faster
• ✓ Prescribe targeted antibiotics instead of broad-spectrum drugs
• ✓ Improve patient survival rates and reduce complications
• ✓ Minimize hospital stays and healthcare costs

Through our technology, we aim to transform the standard of care in infectious disease treatment, making precision medicine accessible and practical for clinicians worldwide.

Ending Antibiotic Resistance as a Global Crisis

We envision a future where antimicrobial resistance no longer poses a threat to global health. Through rapid, comprehensive testing, we believe that: